Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors
Excalipoint Therapeutics, a clinical-stage biotechnology company advancing novel T-cell engager (TCE) therapies for solid tumors and autoimmune disorders, today announced a clinical collaboration with Roche to explore the combination of Excalipoint’s lead product candidate EXP011 (CTM012), a tri-specific T-cell engager targeting DLL3, CD3, and 4-1BB and Roche’s atezolizumab in patients with DLL3-expressing solid tumors.
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies
Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, today announced an oversubscribed $68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs.
